See also the October 2015 report, “Worldwide Wound Management, Forecast to 2024:
Established and Emerging Products, Technologies and Markets
in the Americas, Europe, Asia/Pacific and Rest of World”, Report #S251.
With Medtronic’s pending $42.9 billion purchase of Covidien, the company now has bought itself a seat at the global wound management table. No, this is not a “current” concern for other active wound market companies, since Covidien is not dominant a contender in wound management — the aggregate of its Covidien and Kendall branded products’ presence is a meager 6%.
Source: MedMarket Diligence, LLC; Report #S249.
However, Medtronic never settles for low market share, so it is fair to assume that Medtronic’s planned future involvement in wound management and other of Covidien’s markets is likely to be anything but the “status quo”.